相关临床试验
23
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1876
进行中（未招募）
1
4.3%
已完成
21
91.3%
Unknown
1
4.3%
暂无批准数据
- The CycleTrack study, led by the universities of Bristol and Exeter, will create the world's largest biobank of dried menstrual fluid samples to improve understanding of heavy menstrual bleeding and related conditions. - Heavy menstrual bleeding affects up to half of women worldwide, yet researchers say menstrual health remains poorly understood due to a lack of high-quality data. - The study will recruit thousands of participants from the Children of the 90s and Born in Bradford birth cohorts, collecting real-time symptom data and menstrual fluid samples over three cycles. - Researchers hope the findings will enable earlier diagnosis, more personalised treatment, and new ways to identify health risks such as iron deficiency.
- A triangulation study combining observational, sibling comparison, and Mendelian randomisation analyses found loneliness is linked to poorer mental health, lower wellbeing, and worse general health including multimorbidity. - Social isolation showed a narrower influence, with clearest evidence involving poorer wellbeing, while no consistent evidence linked either experience to specific physical conditions like coronary artery disease or type 2 diabetes. - The study, published in Nature Communications and led by the University of Bristol, Nesta, and Amsterdam UMC, used UK Biobank data from approximately 500,000 participants. - Researchers emphasize that loneliness and social isolation should be examined and addressed separately, as loneliness relates to relationship quality while isolation concerns the quantity of social contacts.
- A James Lind Alliance Priority Setting Partnership led by the University of Bristol has published the top 10 research priorities for childhood food allergy, drawing on input from over 900 survey respondents and a final workshop of 29 stakeholders. - Food allergies affect one in 13 children in the UK, with impacts spanning physical, emotional, and social wellbeing for both children and their families. - The priorities have already informed Natasha's Foundation's £10 million Prize, focusing on the first 1,000 days from conception to age two for prevention and early-life origins research. - The published priorities span prevention, early diagnosis, treatment, causation, eating out safety, care settings, psychosocial impact, emergency anaphylaxis treatment, awareness, and dietary desensitisation strategies.
- The Medical Research Council (MRC) is investing £9.7 million to establish ten Regional Accounts for Clinical Researchers (RACR) across the UK. - The initiative brings together more than 50 research organisations and over 60 NHS organisations across England, Scotland, Wales and Northern Ireland. - The programme will deliver flexible, tailored support to more than 190 clinicians at critical career "pinch points" over the next two years. - The University of Exeter and Royal Devon University Healthcare NHS Foundation Trust will join the Great Western Clinical Research Alliance to support clinical academics.
- A University of Bristol pilot trial demonstrated that tocilizumab, an anti-inflammatory drug used for rheumatoid arthritis, achieved 54% remission rates in treatment-resistant depression patients compared to 31% with placebo. - The study represents the first randomized controlled trial to target the IL-6 receptor pathway for depression treatment, focusing on patients with persistent low-grade systemic inflammation. - Tocilizumab showed superior treatment efficiency with a Number Needed to Treat of 5 compared to SSRIs' NNT of 7, suggesting potential advantages over conventional antidepressants. - The trial enrolled 30 participants with moderate-to-severe depression who had not responded to standard treatments and showed inflammatory markers in blood tests.
- Scarlet Therapeutics demonstrated that its lab-grown universal red blood cells achieve a half-life comparable to normal donated red blood cells in preclinical studies, marking a pivotal validation of the technology. - The company's proprietary immortalized cell line technology enables scalable manufacturing of universal RBCs that can be administered regardless of blood type, removing compatibility constraints. - Scarlet raised £3.2 million in seed funding to advance therapeutic applications targeting metabolic diseases including hyperammonemia and hyperoxaluria. - The platform supports three application areas: therapeutic RBCs for disease treatment, universal transfusion products, and performance-enhancing RBC systems.
- The ARCADIA consortium, funded with £3 million from Arthritis UK, brings together researchers from the UK and Italy to develop accurate methods for determining when inflammatory arthritis patients have achieved true disease-free remission. - Current remission definitions are inadequate, as many patients who stop medications quickly relapse, suggesting underlying disease causes remain present despite symptom control. - The study will analyze tissue samples from patients at different disease stages to develop tools that accurately assess relapse risk, enabling informed treatment decisions. - The research aims to help patients safely discontinue medications and achieve long-lasting, drug-free remission while advancing understanding of inflammatory arthritis root causes.
- Cirrus Therapeutics raised $11 million in seed financing led by ClavystBio to advance its novel AAV gene therapy for dry age-related macular degeneration. - The therapy targets IRAK-M protein restoration, addressing an underlying age-related cause of dry AMD that affects over 200 million people worldwide. - The funding will support IND-enabling studies for the lead program, which aims to provide a one-time treatment alternative to current monthly injections. - Research published in Science Translational Medicine identified IRAK-M as a key immune regulator that decreases with age and more severely in dry AMD patients.
- Evotec has joined the NURTuRE-AKI consortium led by Kidney Research UK to establish the world's most comprehensive patient cohort for acute kidney injury research. - The longitudinal study will collect multi-omics data from 950 patients across three cohorts, including cardiac surgery patients and those experiencing AKI-to-CKD progression. - The initiative aims to identify novel therapeutic targets and biomarkers for AKI, a condition affecting millions worldwide with no current preventive or therapeutic treatments available.
- A three-minute Fastball EEG test successfully identified memory problems linked to Alzheimer's disease in people with mild cognitive impairment before typical diagnosis occurs. - The trial involving 106 participants found that those with amnestic MCI showed reduced brain responses compared to healthy adults, indicating higher Alzheimer's risk. - Cumulus Neuroscience is launching a 1,000-subject study to further validate the at-home EEG headset technology for early Alzheimer's detection. - The passive test could help identify patients who would benefit most from new Alzheimer's drugs like donanemab and lecanemab when treatment is most effective.
